Homepage | Istituto Neuroscienze Firenze

Prof. Pallanti has started prescribing off-label Fluvoxamine, the newly marketed Serotoninergic drug (SSRI).  FDA approval arrived in 1987. Italy was the last of the European countries to guarantee reimbursement for the treatment of Depression with SSRIs in the year 2001. Dr. Pallanti's patients received the innovative treatment 14 years before the others.

Foundation of the Istituto di Neuroscienze.
It was conceived by Dr. Pallanti to conduct research to validate and develop therapeutic innovations to be applied to the clinic for the benefit of patients, and to use the results to design new research.

Opening of the Day-Center where psychological, neuropsychological, and psychometric assessments, clinical interview, and an interview with family members when necessary, are integrated to address calibrated and individualized care.  The maximum of care that reduces the “hospitalization” to minimum. 

The use of infusion therapy, which today seems simple but in the 80s - 90s it was considered an innovation.

Introduction of Plasma Tests for diagnostics

Adoption of a new diagnosis of ADHD.

Starting Life-span ADHD program for children and adults.

Starting a program for behavioral addictions and pathological gambling.

Start of Neuromodulation therapies - Light Tehrapy and PESF

Starting an Adult ADHD program

Starting a PANDAS-PANS program.

Introduction of Pharmacological therapy for Behavioral Addiction

Start of Neuromodulation clinical therapies - rTMS and tDCS

At the time there were few centers in the world where these therapies were operated, also because the FDA approval only took place in 2008. The Istituto di Neuroscienze was an absolute avant-garde in the world.

Introduction of Standard Pharma Supplements for Holistic Care.

Started publishing scientific peer-reviewed articles on clinical use of TMS.

Conducting the Master Course in Mindfulness.

Foundation of the Clinical TMS Society (California, USA) as a founding member.

Introduction of Gut-screening into diagnostics.

Introduction of Psychotherapy combined with Neuromodulation Therapies.

Introduction of RDoC approach based on connectivity in association with Harvard University.

Introduction of Genetic Tests in diagnostics.

Introduction of Theta-Burst TMS stimulation protocols.

Introduction of rTMS for behavioral addictions in collaboration with Harvard University.

Start of Neuromodulation clinical therapies - rTMS and tDCS

At the time there were few centers in the world where these therapies were operated, also because the FDA approval only took place in 2008.

The Istituto di Neuroscienze was an absolute avant-garde in the world.

Introduction of non-invasive Vagus Nerve Stimulation (VNS). 
Introduction of Mindfulness associated with Neuromodulation Therapies (TMS).

Published a peer-reviewed scientific article on how to prevent the Neurocovid: one of the first scientific paper on Covid-19 in the world.

Use of Esketamine Spray (Spravato) for Resistant Depression.

Use of Ketamine Infusion for Resistant Depression.

Publication of major studies on the use of TMS Theta-Burst for Gambling Disorder and tDCS for Mild Cognitive Impairment.
Introduction of Neurofeedback for ADHD.